Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

MErCuRIC-1

Logo

Trial Status: Complete

This is a multi-centre European Phase 1 study of MEK1/2 inhibitor PD-0325901 with c-MET inhibitor PF-02341066 in KRASMT and KRASWT (with aberrant c-MET) Colorectal Cancer Patients.

A Sequential Phase I study of MEK 1/2 inhibitors PD-0325901 or Binimetinib combined with cMET inhibitor PF-02341066 in Patients with RAS Mutant and RAS Wild Type (with aberrant c-MET) Colorectal Cancer

Primary Objectives

Dose Escalation Phase: To assess the safety and toxicity profile of PD-0325901 or Binimetinib/PF-02341066 combination in patients with advanced solid tumours using the NCI CTCAE V4.03, and determine the maximum tolerated dose (MTD).

Dose Expansion Phase: To investigate the response to treatment with RPII dose of PF-02341066 in combination with Binimetinib in patients with RASMT and RASWT/c-MET+ CRC.